Brain metastasis (BM) is associated with a poor prognosis, with the typical overall survival rate ranging from weeks to months in the absence of treatment. Although the concept of immune privilege in the central nervous system has eroded over time, the advent of immunotherapy has opened a new set of potential therapeutic options for patients with BM.
Review Int J Oncol 2020 Sep;57(3):665-677. doi: 10.3892/ijo.2020.5091. Epub 2020 Jun 29.
Development of immunotherapy for brain metastasis (Review)
Ruilin Ding 1, Longxia Chen 2, Zhou Su 3, Tengqiong Xiong 2, Qinglian Wen 4, Qing Peng 5, Feng Jiang 5Affiliations expand
- PMID: 32705149
- DOI: 10.3892/ijo.2020.5091
Abstract
Brain metastasis (BM) is associated with a poor prognosis, with the typical overall survival rate ranging from weeks to months in the absence of treatment. Although the concept of immune privilege in the central nervous system has eroded over time, the advent of immunotherapy has opened a new set of potential therapeutic options for patients with BM. Recently, immunotherapy has been demonstrated to confer survival advantages to patients with multiple malignancies commonly associated with BMs. Data from a number of clinical trials have demonstrated that immune checkpoint inhibitors are effective for patients with BM. In addition, cellular therapies, including the application of chimeric antigen receptors T?cell therapy and dendritic cell vaccine, have also been utilized in the treatment of BM. In the present review, preclinical and clinical evidence supporting the applicability of immunotherapy for the treatment of BMs from melanoma, non?small cell lung cancer (NSCLC) and renal cell carcinoma (RCC) were examined, where the challenges and safety of this treatment modality were also discussed.
Similar articles
- Gastrointestinal cancer stem cells as targets for innovative immunotherapy.Chivu-Economescu M, Necula LG, Matei L, Dragu DL, Neagu AI, Alexiu I, Bleotu C, Diaconu CC.World J Gastroenterol. 2020 Apr 14;26(14):1580-1593. doi: 10.3748/wjg.v26.i14.1580.PMID: 32327907 Free PMC article. Review.
- Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma.Chen L, Douglass J, Kleinberg L, Ye X, Marciscano AE, Forde PM, Brahmer J, Lipson E, Sharfman W, Hammers H, Naidoo J, Bettegowda C, Lim M, Redmond KJ.Int J Radiat Oncol Biol Phys. 2018 Mar 15;100(4):916-925. doi: 10.1016/j.ijrobp.2017.11.041. Epub 2017 Dec 5.PMID: 29485071
- Combination treatments with immunotherapy in brain metastases patients.Henon C, Remon J, Hendriks LE.Future Oncol. 2020 Aug;16(23):1691-1705. doi: 10.2217/fon-2020-0156. Epub 2020 May 15.PMID: 32412817
- Vaccine-Based Immunotherapeutics for the Treatment of Glioblastoma: Advances, Challenges, and Future Perspectives.Cuoco JA, Benko MJ, Busch CM, Rogers CM, Prickett JT, Marvin EA.World Neurosurg. 2018 Dec;120:302-315. doi: 10.1016/j.wneu.2018.08.202. Epub 2018 Sep 6.PMID: 30196171 Review.
- Nanomicelle protects the immune activation effects of Paclitaxel and sensitizes tumors to anti-PD-1 Immunotherapy.Yang Q, Shi G, Chen X, Lin Y, Cheng L, Jiang Q, Yan X, Jiang M, Li Y, Zhang H, Wang H, Wang Y, Wang Q, Zhang Y, Liu Y, Su X, Dai L, Tang M, Li J, Zhang L, Qian Z, Yu D, Deng H.Theranostics. 2020 Jul 9;10(18):8382-8399. doi: 10.7150/thno.45391. eCollection 2020.PMID: 32724476 Free PMC article.
